AIP
TCRX icon

Ameritas Investment Partners’s TScan Therapeutics TCRX Stock Holding History

Ameritas Investment Partners’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,762
Closed -$5.19K – 3341
2025
Q1 		$5.19K Hold
3,762
– – ﹤0.01% 2964
2024
Q4 		$11.4K Hold
3,762
– – ﹤0.01% 2867
2024
Q3 		$18.7K Hold
3,762
– – ﹤0.01% 2692
2024
Q2 		$22K Buy
+3,762
New +$29.6K ﹤0.01% 2570

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ameritas Investment Partners's TCRX Position: Q2 2025 in Review

Ameritas Investment Partners sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 3,762 shares — an estimated $5.19K sold.

Ameritas Investment Partners first reported a position in TCRX in Q2 2024 and held it in 4 quarters. The position peaked at $22K in Q2 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

  • Ameritas Investment Partners reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 3,762 TScan Therapeutics shares in Q2 2025, an estimated $5.19K.
  • Ameritas Investment Partners first reported a position in TScan Therapeutics in Q2 2024 and held it in 4 quarters.
  • Ameritas Investment Partners's TScan Therapeutics position peaked at $22K in Q2 2024.
  • 81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.